U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06857955) titled 'A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients' on March 03.
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Study Start Date: May 05
Study Type: INTERVENTIONAL
Condition:
Hypertension
Intervention:
OTHER: Saline
0.9% sodium chloride saline solution
DRUG: QCZ484
Solution of Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Services with permi...